Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–66 of 66 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Peptic Ulcer Disease Clear all

Conditions: Voice Disorders, Gastroesophageal Reflux
Interventions: Neuromuscular Electrical Stimulation, Unstimulated; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 6 Years to 11 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
Interventions: Clinician Notification with Nurse Facilitation (CNNF), Wait list control; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Obesity, Obesity, Morbid, Obesity Associated Disorder, Bariatric Surgery Candidate, Fistula, Gastric, Roux-en-y Anastomosis Site, Ulcer, Gastric, Abdominal Pain, Abdominal Obesity, Complication of Surgical Procedure, Complication of Treatment, Complication,Postoperative, Weight Gain, Weight Loss, Leak, Anastomotic, Delayed Gastric Emptying Following Procedure
Interventions: Primary Obesity Endoscopic Procedures, Endoscopic Revision of Bariatric Surgical Procedures, Bariatric Surgery Procedures, Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction, Intragastric Balloon, Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal, Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy, Aspiration Therapy; Procedure · Device
Lead sponsor: Christopher C. Thompson, MD, MSc; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peptic Ulcers
Interventions: Celecoxib, Naproxen, ASA; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 23
States / cities: Anaheim, California • San Diego, California • Farmington, Connecticut + 19 more

Conditions: Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions: Not listed
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Marginal Ulcers
Interventions: Omeprazole, Famotidine; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions: Cessation of Acid Suppressing Medications; Other
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gastric Ulcer
Interventions: PA32540, EC-Aspirin 325 mg; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Helicobacter Pylori
Interventions: Phototherapy; Device
Lead sponsor: LumeRx; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Achlorhydria, Gastrinoma, Zollinger Ellison Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuroendocrine Tumors
Interventions: Capecitabine, Temozolomide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Gastrointestinal Bleeding
Interventions: UI-EWD, Conventional therapy; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 22 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Naproxen; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Marginal Ulcer, Chronic Ulcer Disease, Persistent Ulcer Disease, Recurrent Ulcer Disease, Late Morbidity After Gastric Bypass
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fresno, California

Conditions: Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions: S-Tenatoprazole-Na (STU-Na); Drug
Lead sponsor: STEBA France; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Quantifying Effects of Treatment of Pediatric Dysphonia

Anticoagulation With Enhanced Gastrointestinal Safety

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Endoscopic Metabolic and Bariatric Therapies

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

Systems Biology of Gastrointestinal and Related Diseases

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

Ulcer Prevention Study in Post Gastric Bypass Patients

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

Feasibility Study of Phototherapy System to Treat H Pylori

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Evaluating Patients With Abnormal Levels of Gastric Acid

Capecitabine and Temozolomide for Neuroendocrine Cancers

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

Chronic Marginal Ulcers After Gastric Bypass

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers